Skip to main content

XDx Gets CTAF Recommendation for AlloMap Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that the California Technology Assessment Forum has recommended the use of its AlloMap gene expression test.

The Brisbane, Calif.-based firm said that CTAF, which is a non-profit entity sponsored by Blue Shield of California to assess new and emerging medical technology, agreed that AlloMap met all five technology assessment criteria for safety, effectiveness, and improvement in health outcomes.

The test was cleared by the US Food and Drug Administration in 2008 and is used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection. It is used in conjunction with a standard clinical assessment.

"CTAF's independent and unbiased recommendations are an important decision-making resource for clinicians and patients, and the CTAF recommendation further validates AlloMap as an important alternative to invasive endomyocardial biopsy in the management of stable heart transplant recipients — one that can have a significant impact on patient quality of life," Pierre Cassigneul, president and CEO of XDx, said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.